317 related articles for article (PubMed ID: 37130090)
1. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.
Cuchel M; Raal FJ; Hegele RA; Al-Rasadi K; Arca M; Averna M; Bruckert E; Freiberger T; Gaudet D; Harada-Shiba M; Hudgins LC; Kayikcioglu M; Masana L; Parhofer KG; Roeters van Lennep JE; Santos RD; Stroes ESG; Watts GF; Wiegman A; Stock JK; Tokgözoğlu LS; Catapano AL; Ray KK
Eur Heart J; 2023 Jul; 44(25):2277-2291. PubMed ID: 37130090
[TBL] [Abstract][Full Text] [Related]
2. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.
Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AF; Stroes E; Taskinen MR; Wiegman A; Wiklund O; Chapman MJ;
Eur Heart J; 2014 Aug; 35(32):2146-57. PubMed ID: 25053660
[TBL] [Abstract][Full Text] [Related]
3. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
4. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
France M; Rees A; Datta D; Thompson G; Capps N; Ferns G; Ramaswami U; Seed M; Neely D; Cramb R; Shoulders C; Barbir M; Pottle A; Eatough R; Martin S; Bayly G; Simpson B; Halcox J; Edwards R; Main L; Payne J; Soran H;
Atherosclerosis; 2016 Dec; 255():128-139. PubMed ID: 27839699
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement.
Bruckert E
Atheroscler Suppl; 2014 Sep; 15(2):26-32. PubMed ID: 25257074
[TBL] [Abstract][Full Text] [Related]
6. Homozygous familial hypercholesterolaemia: update on management.
France M
Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
[TBL] [Abstract][Full Text] [Related]
7. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study.
D'Erasmo L; Steward K; Cefalù AB; Di Costanzo A; Boersma E; Bini S; Arca M; van Lennep JR;
Eur J Prev Cardiol; 2022 May; 29(5):832-841. PubMed ID: 34971394
[TBL] [Abstract][Full Text] [Related]
9. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
[TBL] [Abstract][Full Text] [Related]
10. [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF)].
Ascaso JF; Mata P; Arbona C; Civeira F; Valdivielso P; Masana L
Clin Investig Arterioscler; 2015; 27(2):80-96. PubMed ID: 25757840
[TBL] [Abstract][Full Text] [Related]
11. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ
Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419
[TBL] [Abstract][Full Text] [Related]
12. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
Bajaj A; Cuchel M
J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
[TBL] [Abstract][Full Text] [Related]
13. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
[TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.
Ben-Omran T; Masana L; Kolovou G; Ariceta G; Nóvoa FJ; Lund AM; Bogsrud MP; Araujo M; Hussein O; Ibarretxe D; Sanchez-Hernández RM; Santos RD
Adv Ther; 2019 Jul; 36(7):1786-1811. PubMed ID: 31102204
[TBL] [Abstract][Full Text] [Related]
15. A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting.
Blom DJ; Gaudet D; Hegele RA; Patel DS; Cegla J; Kolovou G; Marin LM
Adv Ther; 2022 Apr; 39(4):1857-1870. PubMed ID: 35194765
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
Ito MK; Watts GF
Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
[TBL] [Abstract][Full Text] [Related]
17. Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study.
Jiang L; Stoekenbroek RM; Zhang F; Wang Q; Yu W; Yuan H; Cai G; Chen Y; Li G; Yang Y; Zhang Y; Cheng X; Zhu H; Zhou H; Ye P; Yan S; Wang X; Wu W; Li R; Xie J; Jiao J; Cheng S; Niu W; Chen J; Yang S; Zhou Y; Kastelein JJP; Yang Y; Wang L
J Clin Lipidol; 2022; 16(3):306-314. PubMed ID: 35379578
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry.
Cuchel M; Lee PC; Hudgins LC; Duell PB; Ahmad Z; Baum SJ; Linton MF; de Ferranti SD; Ballantyne CM; Larry JA; Hemphill LC; Kindt I; Gidding SS; Martin SS; Moriarty PM; Thompson PP; Underberg JA; Guyton JR; Andersen RL; Whellan DJ; Benuck I; Kane JP; Myers K; Howard W; Staszak D; Jamison A; Card MC; Bourbon M; Chora JR; Rader DJ; Knowles JW; Wilemon K; McGowan MP
J Am Heart Assoc; 2023 May; 12(9):e029175. PubMed ID: 37119068
[TBL] [Abstract][Full Text] [Related]
19. New algorithms for treating homozygous familial hypercholesterolemia.
Tromp TR; Cuchel M
Curr Opin Lipidol; 2022 Dec; 33(6):326-335. PubMed ID: 36206078
[TBL] [Abstract][Full Text] [Related]
20. Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting.
Mahzari M; Zarif H
Adv Ther; 2021 May; 38(5):2159-2169. PubMed ID: 33829367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
